Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K S Vaddadi

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Psychopharmacology|January 1, 1986
A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patientsK S Vaddadi, C J Gilleard, R H Mindham, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 15, 1998
Cue dependent right hemineglect in schizophrenia: a kinematic analysisM E Downing, J G Phillips, J L Bradshaw, et al.
Neuropsychologia|September 2, 1998
Response programming in patients with schizophrenia: a kinematic analysisM E Downing, J G Phillips, J L Bradshaw, et al.
Psychiatry Research|March 1, 1989
A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesiaK S Vaddadi, P Courtney, C J Gilleard, et al.
Schizophrenia Research|July 5, 1996
Schizophrenia, tardive dyskinesia and essential fatty acidsK S Vaddadi, C J Gilleard, E Soosai, et al.
Neuroscience|January 11, 2002
Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's diseaseJ J Clifford, J Drago, A L Natoli, et al.
Pharmatherapeutica|January 1, 1985
A clinical assessment of zuclopenthixol dihydrochloride (Clopixol tablets) in the treatment of psychotic illnessB S Mann, K S Moslehuddin, R T Owen, et al.
Schizophrenia Research|April 1, 1994
A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseasesA I Glen, E M Glen, D F Horrobin, et al.
Neurology|July 27, 2005
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trialB K Puri, B R Leavitt, M R Hayden, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Psychopharmacology|January 1, 1986
A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patientsK S Vaddadi, C J Gilleard, R H Mindham, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 15, 1998
Cue dependent right hemineglect in schizophrenia: a kinematic analysisM E Downing, J G Phillips, J L Bradshaw, et al.
Neuropsychologia|September 2, 1998
Response programming in patients with schizophrenia: a kinematic analysisM E Downing, J G Phillips, J L Bradshaw, et al.
Psychiatry Research|March 1, 1989
A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesiaK S Vaddadi, P Courtney, C J Gilleard, et al.
Schizophrenia Research|July 5, 1996
Schizophrenia, tardive dyskinesia and essential fatty acidsK S Vaddadi, C J Gilleard, E Soosai, et al.
Neuroscience|January 11, 2002
Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's diseaseJ J Clifford, J Drago, A L Natoli, et al.
Pharmatherapeutica|January 1, 1985
A clinical assessment of zuclopenthixol dihydrochloride (Clopixol tablets) in the treatment of psychotic illnessB S Mann, K S Moslehuddin, R T Owen, et al.
Schizophrenia Research|April 1, 1994
A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseasesA I Glen, E M Glen, D F Horrobin, et al.
Neurology|July 27, 2005
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trialB K Puri, B R Leavitt, M R Hayden, et al.
Pageof 2